Payment overview · 2025
General Payments
$683.13
45 reported records · 11 companies
Healthcare provider profile · identity verified
Snesha H Modi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · EVANSVILLE, IN · NPI 1366616435
Verified facts
What the public records show
CMS Open Payments records show Snesha H Modi, M.D. received $683.13 in general payments during 2025 across 45 reported records.
ABBVIE INC. accounted for 42.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $289.36 | 42.4% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $114.32 | 16.7% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $77.38 | 11.3% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.66 | 7.0% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $35.06 | 5.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.89 | 5.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.74 | 3.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.86 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.72 | 2.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.96 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.18 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $683.13 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $180.23 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $179.85 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $114.32 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $85.75 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.66 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.80 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.80 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $35.06 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.58 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.06 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 943 | 234 |
| Amlodipine Besylate | Amlodipine Besylate | 788 | 192 |
| Losartan Potassium | Losartan Potassium | 572 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 553 | 124 |
| Lisinopril | Lisinopril | 468 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 372 | 91 |
| Omeprazole | Omeprazole | 353 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 60 |
| Gabapentin | Gabapentin | 212 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 53 |
| Metformin Hcl | Metformin Hcl | 179 | 47 |
| Furosemide | Furosemide | 174 | 51 |
| Potassium Chloride | Potassium Chloride | 167 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 43 |
| Sertraline Hcl | Sertraline Hcl | 160 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 46 |
| Famotidine | Famotidine | 151 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 147 | 38 |
| Simvastatin | Simvastatin | 145 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 138 | 35 |
| Metformin Hcl Er | Metformin Hcl | 129 | 33 |
| Trazodone Hcl | Trazodone Hcl | 123 | 29 |
| Lorazepam | Lorazepam | 121 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 25 |
| Allopurinol | Allopurinol | 113 | 31 |
| Atenolol | Atenolol | 104 | 27 |
| Montelukast Sodium | Montelukast Sodium | 101 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 31 |
| Alprazolam | Alprazolam | 84 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 82 | 19 |
| Eliquis | Apixaban | 82 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 20 |
| Synthroid | Levothyroxine Sodium | 73 | 16 |
| Meloxicam | Meloxicam | 72 | 19 |
| Ezetimibe | Ezetimibe | 71 | 18 |
| Glimepiride | Glimepiride | 69 | 16 |
| Glipizide Er | Glipizide | 66 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 19 |
| Tramadol Hcl | Tramadol Hcl | 61 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 14 |
| Clonidine Hcl | Clonidine Hcl | 52 | 15 |
| Valsartan | Valsartan | 52 | 13 |
| Alendronate Sodium | Alendronate Sodium | 51 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 12 |
| Carvedilol | Carvedilol | 45 | 15 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Ozempic | Semaglutide | 45 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 12 |
| Azithromycin | Azithromycin | 43 | 39 |
| Irbesartan | Irbesartan | 43 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | 12 |
| Jardiance | Empagliflozin | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 11 |
| Glipizide | Glipizide | 41 | 13 |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | 13 |
| Temazepam | Temazepam | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 32 |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Klor-Con M20 | Potassium Chloride | 36 | 13 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 31 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 32 | 27 |
| Methylprednisolone | Methylprednisolone | 32 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 28 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 25 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 11 |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 13 |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $683.13 · 45 records | ABBVIE INC. | ABRYSVO, AREXVY, COMIRNATY, EVENITY, INSPIRE, LEQVIO, MOUNJARO, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, WATCHMAN FLX, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error